HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for ...

Zura Bio Limited (NASDAQ:ZURA – Free Report) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Zura Bio in a note issued to investors on ...

Belite Bio, Inc (NASDAQ:BLTE – Free Report) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued on Tuesday, March ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Cabaletta Bio (NasdaqGS:CABA) with a Overweight recommendation. As of October 30, 2025, the average one-year price ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Overweight recommendation. As of April 24, 2025, the average one-year price target for ...

Cantor Fitzgerald assumed coverage of Belite Bio (BLTE) with an Overweight rating and $154 price target Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the ...